Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

It's a companion shot to Merck's Vaxneuvance (formerly V114), which covers 15 serotypes and was approved by the FDA last year as a rival to Pfizer's Prevnar 13 and newer Prevnar 20 vaccines, which ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...